Search results
Results from the WOW.Com Content Network
Drug disposal programs have been cited as an effective tool in the fight against opioid abuse by medical studies and the White House. Now Google is lending a hand by pinpointing 3,500 of these ...
Glipizide, sold under the brand name Glucotrol among others, is an anti-diabetic medication of the sulfonylurea class used to treat type 2 diabetes. [1] [2] It is used together with a diabetic diet and exercise. [1] [2] It is not indicated for use by itself in type 1 diabetes. [1] [2] It is taken by mouth.
The take-back events are part of a mission to create safe medication disposal sites, prevent drug diversion or transfer of the prescribed drug for illicit use, and provide education for the public. [29] In April 2021, the program reported the collection of 420 short tons (380,000 kg) of drugs at 5,060 sites around the country. [28]
World-leading organizations such as WHO and UNICEF recommended several appropriate and safe drug disposal options and drug use prevention. With large supplies of drugs, drug pollution and negative environmental impact of pharmaceuticals and personal care products becomes a concern. Also, drug recycling might be a possibility.
Prescription drug monitoring programs, or PDMPs, are an example of one initiative proposed to alleviate effects of the opioid crisis. [1] The programs are designed to restrict prescription drug abuse by limiting a patient's ability to obtain similar prescriptions from multiple providers (i.e. “doctor shopping”) and reducing diversion of controlled substances.
Between 1984 and 1999, the number of defendants charged with a drug offense in the Federal courts increased 3% annually, from 11,854 to 29,306. By 1999 there were 472 Drug Courts in the nation and by 2005 that number had increased to 1262 with another 575 Drug Courts in the planning stages; currently, all 50 states have working Drug Courts ...
The group suing the FDA has asked for a preliminary injunction to take one of the two drugs used in a medication abortion, mifepristone, off the market while the case plays out.
Alogliptin, sold under the brand names Nesina and Vipidia, [2] [3] is an oral anti-diabetic drug in the DPP-4 inhibitor (gliptin) class. [4] Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of hypoglycemia, and has relatively modest glucose-lowering activity. [1]